Holen Sie sich die Stockscreener-App
14.68
2.13%
-0.32
Handel nachbörslich:
14.68
Schlusskurs vom Vortag:
$15.00
Offen:
$15
24-Stunden-Volumen:
343.09K
Relative Volume:
0.74
Marktkapitalisierung:
$1.01B
Einnahmen:
$26.98M
Nettoeinkommen (Verlust:
$-180.66M
KGV:
-3.1368
EPS:
-4.68
Netto-Cashflow:
$-63.56M
1W Leistung:
+6.30%
1M Leistung:
-27.90%
6M Leistung:
-27.40%
1J Leistung:
-18.81%
1-Tages-Spanne:
$14.64
$15.30
1-Wochen-Bereich:
$13.88
$17.04
52-Wochen-Spanne:
$12.17
$28.67
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Firmenname
Bicycle Therapeutics Plc Adr
Sektor
Branche
Telefon
011441223261503
Adresse
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Vergleichen Sie BCYC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
14.68 | 1.01B | 26.98M | -180.66M | -63.56M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | Stephens | Equal-Weight |
| 2024-09-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-07 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | Eingeleitet | Cowen | Outperform |
| 2022-07-28 | Eingeleitet | Barclays | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-04-13 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-02-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-12-09 | Eingeleitet | Needham | Buy |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Buy |
| 2021-04-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2020-04-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-14 | Eingeleitet | ROTH Capital | Buy |
| 2019-09-11 | Hochstufung | Goldman | Neutral → Buy |
| 2019-06-17 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-17 | Eingeleitet | Goldman | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
| 2019-06-17 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Bicycle Therapeutics Plc Adr Aktie (BCYC) Neueste Nachrichten
Bicycle Therapeutics' SWOT analysis: stock outlook amid clinical trials and cash strength - Investing.com India
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data - Investing.com
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - Yahoo Finance
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study - Yahoo Finance
Pharmacovigilance and Drug Safety Software Market Size to Reach USD 371.88 Million by 2032, Growing at a 6.76% CAGR – SNS Insider - Yahoo Finance
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study - Yahoo Finance
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potential - Investing.com India
Bicycle Therapeutics' chief accounting officer sells shares worth $157,113 - Investing.com
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus - Yahoo Finance
Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform - Investing.com India
Bicycle Therapeutics retains stock target and Buy rating on promising data - Investing.com
Bicycle Therapeutics spotlights cancer treatment targets - Investing.com
Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - MSN
A company insider recently sold 3,212 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You also Consider to Sale? – Knox Daily - Knox Daily
BCYC’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Keeping an Eye on Bicycle Therapeutics Plc ADR (BCYC) After Insider Trading Activity - Knox Daily
Bicycle Therapeutics Plc ADR (BCYC)’s stock price range in the last year - US Post News
Bicycle therapeutics executive sells shares worth over $21k - Investing.com India
Bicycle therapeutics executive sells shares to cover tax obligations - Investing.com India
Bicycle therapeutics COO sells shares worth over $21k - Investing.com India
Bicycle therapeutics CEO sells shares worth over $71k - Investing.com
Bicycle therapeutics CTO sells shares worth over $21k - Investing.com
Bicycle therapeutics executive sells shares worth over $5,000 - Investing.com
CHIEF PROD & SUPPLY CHAIN OFF Hannay Michael Charles Ferguso sale 246 shares of Bicycle Therapeutics Plc ADR [BCYC] – Knox Daily - Knox Daily
Bicycle Therapeutics Plc ADR (BCYC)’s stock chart: A technical perspective - US Post News
Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 22.56 - The Dwinnex
Bayer Reports Positive Safety Data on Parkinson's Disease Drug - Yahoo Finance
Wall Street SWOT: Bicycle Therapeutics stock rides high on cancer drug promise - Investing.com
A company insider recently sold 246 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You Sale? - Knox Daily
Nothing is Better Than Bicycle Therapeutics Plc ADR (BCYC) stock at the moment - SETE News
RBC Capital Mkts initates Bicycle Therapeutics Plc ADR (BCYC) stock to an Outperform - Knox Daily
Metric Analysis: Bicycle Therapeutics Plc ADR (BCYC)’s Key Ratios in the Limelight - The Dwinnex
Bicycle Therapeutics Plc ADR: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Are Bicycle Therapeutics Plc ADR (BCYC) shares a good deal now? - US Post News
Hain Celestial Group Inc [HAIN] Investment Guide: What You Need to Know - Knox Daily
Bicycle Therapeutics stock maintains Buy rating post-ESMO data By Investing.com - Investing.com UK
Bicycle Therapeutics Plc ADR [BCYC] Shares Fall -0.26 % on Wednesday - Knox Daily
A stock that deserves closer examination: Bicycle Therapeutics Plc ADR (BCYC) - US Post News
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy - Yahoo Finance
Bicycle Therapeutics Plc ADR (BCYC) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone - Yahoo Finance
Aqua Metals Inc [AQMS] Shares Fall Approximately -81.89% Over the Year - Knox Daily
Taking a look at what insiders are doing to gauge the Interface Inc. [TILE] - Knox Daily
Sleep Number Corp [SNBR] Director makes an insider purchase of 43,000 shares worth 0.53 million. - Knox Daily
Top investors say Bicycle Therapeutics Plc ADR (BCYC) ticks everything they need - SETE News
Finanzdaten der Bicycle Therapeutics Plc Adr-Aktie (BCYC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bicycle Therapeutics Plc Adr-Aktie (BCYC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director |
Dec 16 '24 |
Buy |
15.34 |
500,000 |
7,670,900 |
9,995,274 |
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER |
Nov 11 '24 |
Option Exercise |
5.67 |
2,575 |
14,608 |
24,234 |
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER |
Nov 11 '24 |
Sale |
25.11 |
6,256 |
157,114 |
19,241 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):